The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test

Hobson, Peter

doi:10.1093/ageing/28.1.39

Cited by 87 publications

(68 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence. There was one Class I 15 and one Class III study. 16 In the Class I study, the Cambridge Cognitive Examination (CAMCog) and Mini-Mental State Examination (MMSE) were administered to 126 patients older than 60 years treated for PD in the community and institutions.…”

Section: R E T I R E D R E T I R E Dmentioning

confidence: 99%

“…34 Screening tools for psychosis should be sensitive to hallucinations as well as other psychosis features such as delusions. Only one study evaluated the PPRS, 15 which may be appropriate for patients with PD. 15 However, in order to determine its specificity, the PPRS needs to be evaluated in nonpsychotic and psychotic PD patients.…”

Section: Question 2c In Patients With Pd and Psychosis What Is The mentioning

confidence: 99%

See 1 more Smart Citation

Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): [RETIRED]

Aarsland

Emre²,

Lees³

et al. 2006

Neurology

451

250

View full text Add to dashboard Cite

Abstract-Objective:To make evidence-based treatment recommendations for patients with Parkinson disease (PD) with dementia, depression, and psychosis based on these questions: 1) What tools are effective to screen for depression, psychosis, and dementia in PD? 2) What are effective treatments for depression and psychosis in PD? 3) What are effective treatments for PD dementia or dementia with Lewy bodies (DLB)? Methods: A nine-member multispecialty committee evaluated available evidence from a structured literature review using MEDLINE, and the Cochrane Database of Health and Psychosocial Instruments from 1966 to 2004. Additional articles were identified by panel members. Results: The Beck Depression Inventory-I, Hamilton Depression Rating Scale, and Montgomery Asberg Depression Rating Scale should be considered to screen for depression in PD (Level B). The Mini-Mental State Examination and the Cambridge Cognitive Examination should be considered to screen for dementia in PD (Level B). Amitriptyline may be considered to treat depression in PD without dementia (Level C). For psychosis in PD, clozapine should be considered (Level B), quetiapine may be considered (Level C), but olanzapine should not be considered (Level B). Donepezil or rivastigmine should be considered for dementia in PD (Level B) and rivastigmine should be considered for DLB (Level B). Conclusions: Screening tools are available for depression and dementia in patients with PD, but more specific validated tools are needed. There are no widely used, validated tools for psychosis screening in Parkinson disease (PD). Clozapine successfully treats psychosis in PD. Cholinesterase inhibitors are effective treatments for dementia in PD, but improvement is modest and motor side effects may occur. NEUROLOGY 2006;66:996-1002 Statement of purpose.The Quality Standards Subcommittee (QSS) develops scientifically sound, clinically relevant practice parameters to guide the practice of neurology. This article discusses treatments for the management of patients with depression, psychosis, and dementia in Parkinson disease (PD). These recommendations address the needs of neurologists and other clinicians caring for people with PD, patients and caregivers, research funding agencies, and researchers in movement disorders.Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the April 11 issue to find the title link for this article. R E T I R E D R E T I R E DThis guideline provides answers to the following questions:1. In patients with PD, what are the most accurate tools to screen for depression, psychosis, and dementia? 2. In patients with PD, what are the best treatments for depression and psychosis? 3. What is the most effective treatment of dementia in PD or dementia with Lewy bodies (DLB)?Background and justification. PD is the second most common neurodegenerative disease. 1 Characterized by the cardinal signs of bradykinesia, rigidity, tremor at rest, and abnor...

show abstract

Section: R E T I R E D R E T I R E Dmentioning

confidence: 99%

Section: Question 2c In Patients With Pd and Psychosis What Is The mentioning

confidence: 99%

Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): [RETIRED]

Aarsland

Emre²,

Lees³

et al. 2006

Neurology

451

250

View full text Add to dashboard Cite

show abstract

“…The pre-morbid level of intelligence was measured using the National Adult Reading Test (NART; Nelson and O'Connell 1978). Global cognitive function was examined using the CAMCOG scale (Hobson and Meara 1999). Disease duration was based on the patients' subjective estimate of the time of occurrence of the first motor symptoms.…”

Section: Subject Characteristicsmentioning

confidence: 99%

Increased cortico-cortical functional connectivity in early-stage Parkinson's disease: An MEG study

Stoffers

Bosboom

Deijen³

et al. 2008

NeuroImage

161

141

View full text Add to dashboard Cite

We set out to determine whether changes in resting-state corticocortical functional connectivity are a feature of early-stage Parkinson's disease (PD), explore how functional coupling might evolve over the course of the disease and establish its relationship with clinical deficits.Whole-head magnetoencephalography was performed in an eyesclosed resting-state condition in 70 PD patients with varying disease duration (including 18 recently diagnosed, drug-naive patients) in an "OFF" medication state and 21 controls. Neuropsychological testing was performed in all subjects. Data analysis involved calculation of three synchronization likelihood (SL, a general measure of linear and non-linear temporal correlations between time series) measures which reflect functional connectivity within (local) and between (intrahemispheric and interhemispheric) ten major cortical regions in five frequency bands.Recently diagnosed, drug-naive patients showed an overall increase in alpha1 SL relative to controls. Cross-sectional analysis in all patients revealed that disease duration was positively associated with alpha2 and beta SL measures, while severity of parkinsonism was positively associated with theta and beta SL measures. Moderately advanced patients had increases in theta, alpha1, alpha2 and beta SL, particularly with regard to local SL. In recently diagnosed patients, cognitive perseveration was associated with increased interhemispheric alpha1 SL.Increased resting-state cortico-cortical functional connectivity in the 8-10 Hz alpha range is a feature of PD from the earliest clinical stages onward. With disease progression, neighboring frequency bands become increasingly involved. These findings suggest that changes in functional coupling over the course of PD may be linked to the topographical progression of pathology over the brain.

show abstract

“…6 In contrast, the more comprehensive Cambridge Cognitive Examination (CAMCOG) has a specificity of 94 per cent and includes additional test items of orientation, concentration, expression, memor y, abstract thinking, drawing, comprehension and writing. 7 Both CAMCOG and the MMSE were recommended by the American Academy of Neurology (AAN) as practice parameters for dementia in PD. 6 Several definitions of dementia in PD have been used in clinical and research settings, eg DSM-IV criteria and Cummings and Benson criteria; 8,9 however, until the Movement Disorders Society publishes their diagnostic criteria there is no universally accepted definition.…”

Section: Discussionmentioning

confidence: 99%

A UK survey of treatment of dementia in Parkinson's disease

Leroi¹,

Daniel²,

Fletcher³

et al. 2007

Prog Neurol Psychiatry

View full text Add to dashboard Cite

Clinical experience with antidementia drugs in dementia in Parkinson's disease (PDD) is still limited and a lack of diagnostic criteria and specific screening tests further complicates clinical decision making. Here, the authors discuss the results of a postal survey sent to PD clinicians in the UK to assess their methods of diagnosis and use of antidementia drugs in PDD patients. Copyright © 2007 Wiley Interface Ltd

show abstract

The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test

Cited by 87 publications

References 31 publications

Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): [RETIRED]

Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): [RETIRED]

Increased cortico-cortical functional connectivity in early-stage Parkinson's disease: An MEG study

A UK survey of treatment of dementia in Parkinson's disease

Contact Info

Product

Resources

About